Emerging Agents in GVHD: Axatilimab : vimarsana.com

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Corey Cutler , Hannah Choe , Mitchell Horwitz , Bin Chen , Ohio State University , Marrow Transplant Program At Duke University , Professor Of Medicine At Harvard Medical School , Cell Therapy Program At Massachusetts , Cell Therapy Program , Massachusetts General Hospital , Harvard Medical School , Stem Cell Transplant Program , Adult Blood , Marrow Transplant Program , Duke University , Assistant Professor , Ohio State , Chronic Graft Versus Host Disease , Cgvhd , Csf 1r Inhibitor , Iv Infusion , Agave 201 , Ruxolitinib , Ibrutinib , Belumosudil , Ast Alt Levels , Combination Therapy , Dash Conference , Monoclonal Antibody , Kupffer Cells ,